TAG’s comprehensive analysis found that the public invested at least $252 million USD in the research and development of GeneXpert diagnostic technology, which stands in stark contrast to the lack of affordable pricing and favorable service and maintenance terms from the diagnostics company Cepheid.
Pipeline Report provides an overview of research and provides an overview of research and development of innovations for diagnosing, preventing, treating, and curing HIV, hepatitis C virus (HCV), and tuberculosis (TB).
On June 24, TAG submitted testimony to the Senate Subcommittee on Labor, Health and Human Services, Education, and Related Agencies outlining funding priorities for fiscal year 2022.
TAG joins the U.S. National TB Controllers Association (NTCA) in celebrating our dedicated and brilliant Senior Government Relations and Policy Officer, Elizabeth (Lizzy) Lovinger, who today received the 2021 Charles DeGraw TB Advocacy Award.
On November 16, we honored CDC Director Rochelle Walensky, MD, MPH; Ivy Kwan Arce, activist, mother, and artist living with HIV; and Erica Lessem, MPH, former TAG Deputy Executive Director.
As the HIV epidemic changes over time, and new pandemics continue to emerge, TAG continues to evolve while remaining true to our activist roots. We partner with the most affected communities in the U.S. and around the world.
The bill, S4807A (Stavisky) / A6476A (Hyndman), improves preventive viral hepatitis vaccine access, and is particularly important for people who use drugs and unhoused New Yorkers.
Storytelling is a tool that can help build understanding, support discussions between members of affected communities and other stakeholders, and aid in the identification of important issues and potential solutions. These storyboards follow three individuals journeys through diagnosis, treatment and care, and the barriers they face.
The Time for $5 Coalition, comprised of over 150 civil society organizations globally, calls out Cepheid for the company’s insufficient and self-serving GeneXpert pricing packages for low- and middle-income countries (LMICs), announced May 6, 2021.
This publication explores the critical role the Tuberculosis Trials Consortium holds in increasing the store of knowledge about TB cures and other tools, demonstrates the implications that a lack of funding will have across the TB pipeline, and offers recommendations to ensure the gains made in TB research are not lost.